Instructions for Credit — This activity is accredited for 1.75 continuing education credits for nurse practitioners, nurses, and pharmacists. Participants must attend the free webinar in its entirety, submit the online evaluation form and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
For Pharmacists Credit — Upon completion of the evaluation form, your participation in this educational activity will be reported to the NABP within 2 weeks. Please check mycpemonitor.com after 2 weeks to ensure acceptance of reporting of participation. Please contact firstname.lastname@example.org if you need assistance.
Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or email@example.com.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Advanced practice providers, nurses, and pharmacists involved in the care of patients with hematologic malignancies.
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the types of hematopoietic cell transplantation used in the treatment of blood cancers, including autologous, allogeneic, and reduced-intensity allogeneic stem-cell transplantation|
|•||Identify the methods of stem-cell collection used in patients with blood cancers|
|•||Explain the overarching goals of hematopoietic cell transplantation for all types of blood cancers|
|•||Explain hematopoietic cell transplantation as a treatment option for blood cancers|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of hematopoietic cell transplantation|
|•||Describe the roles of the advanced practice provider, nurse, pharmacist, and the social worker in treating patients with HCT|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Pharmacists
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.75 continuing education contact hours through the California Board of Registered Nursing.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Please click here for test blueprint and points information.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0468-9999-20-020-H01-P
Type of Activity: Knowledge
For questions, grievances, or assistance with special needs (physical, etc.) please contact us at ProfEducation@LLS.org.
Disclosure & Conflict of Interest Policy — The Medical Learning Institute, Inc. (MLI) requires faculty, planners, staff, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they, and their spouse/life partners, may have as related to the content of this activity. These disclosures will be provided to learners prior to the start of the activity. All identified COI are thoroughly vetted and resolved according to MLI policy. MLI is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planning Committee Disclosures — The planners from Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society, the accredited providers, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this accredited CNE/CPE activity during the past 12 months unless listed below.
Teresa Haile, RPh, MBA, Pharmacy Planner, MLI, has nothing to disclose.
Disclosure of Unlabeled Use — This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Ran Reshef, MD, MSc, Consultant: Celgene, Gilead, Monsanto (Bayer), Novartis Pharmaceuticals.
|Rachel Abramova, Pharm D, has nothing to disclose.|
Corinne Shamehdi, MPAS, PA-C, Consultant: Kite, A Gilead Company.
Krista McCarthy, LCSW, has nothing to disclose.
Alison Hoffman, LMSW, has nothing to disclose.
Content/Peer Reviewer Disclosures
Elsa Delille, MSN, FNP-BC, has nothing to disclose.
Disclaimer — Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|Estimated time to complete activity: 1.75 hours|
|Date of initial release: August 25, 2020|
|Valid for CE credit through: October 31, 2021|
Ran Reshef, MD, MSc, is the Director of Translational Research in the Blood and Marrow Transplantation and Cell Therapy Program at Columbia University Medical Center. He is the clinical lead of the CAR-T cell program for both commercially available CAR-T and experimental cell therapies that are still in clinical trials. He directs a research lab in the Columbia Center for Translational Immunology and he is a member of the Herbert Irving Comprehensive Cancer Center.
Dr. Reshef’s research revolves around immunotherapy approaches for the treatment of cancer and his lab studies novel ways to improve the efficacy and the safety of immunotherapies including bone marrow transplants, checkpoint inhibitors and CAR-T cells. He has authored or co-authored more than 60 original research publications related to cancer and bone marrow transplantation and has received research funding from the Leukemia & Lymphoma Society, National Cancer Institute, Conquer Cancer Foundation, Department of Defense, National Marrow Donor Program and the American Society of Hematology.
Rachel Abramova, PharmD, currently serve as the Clinical Pharmacy Manager for Stem Cell Transplant/Multiple Myeloma at New York Presbyterian/Columbia University Irving Medical Center in New York, NY. She graduated with her Doctorate in Pharmacy from St. John’s university and completed both her PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at NewYork-Presbyterian Hospital. In her PGY2 year she served as Chief Resident. Rachel work with the inpatient stem cell transplant/multiple myeloma team to ensure safe use of chemotherapy and assists in supportive care and management of their patient population.
Corinne Shamehdi, MPAS, PA-C, holds a Master of Physician Assistant Studies degree from the University of Florida. Corinne is an Advanced Physician Assistant and the Cellular Therapy Lead for the inpatient Blood and Marrow Transplant Program at New York Presbyterian/Columbia University Irving Medical Center in New York, NY.
Krista McCarthy, LCSW, is a licensed clinical social worker covering all outpatient hematology oncology divisions– multiple myeloma, leukemia, lymphoma, the blood and marrow transplant and cellular therapy services- of New York Presbyterian. She began her NYP career in 2017, initially filling the role of outpatient BMT and myeloma social worker. The following year her practice grew to include the remaining hematology oncology service lines.
Ms. McCarthy earned her MSW from Touro College (NYC) ten years ago. Her career to this point has been exclusive to the medical field with past positions in pediatric critical care, dialysis and radiation oncology. She holds SIFI certification and enjoys supervising MSW students. She has also completed post-graduate certification training in trauma therapy, meaning centered psychotherapy and is an NYP Palliative Care Champion as well as a member of the Association of Oncology Social Work
Alison Hoffman, LMSW, works as an Inpatient Hematology Oncology and BMT program Social Worker at NewYork-Presbyterian Hospital, Columbia University Irving Medical Center in New York, NY. Alison has been working with hematology/oncology patients on the bone marrow transplant unit since 2016.
Alison graduated from Rutgers University with a B.A. in Journalism and Media Studies and from Monmouth University with an Master of Social Work. Alison has been able to apply her journalism background to working with patients and their families and learning about the unique needs that impact the BMT population. Alison is a member of the Association of Oncology Social Work and has previously presented at their annual conference on the needs of post-transplant survivors. Alison is also an NYP Palliative Care Champion and is on the Social Work Board at the Bone Marrow and Cancer Foundation.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Treating Blood Cancers podcasts: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
HCT Specific Resources – www.LLS.org/HCT
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with an LLS Clinical Trial Nurse Navigator who will help find clinical trials and personally assist throughout the clinical trial process, providing an additional resource to the HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists
If you have any questions, please contact us at ProfEducation@LLS.org or call our Information Resource staff at 800-955-4572.